Ongoing treatment(s)-Biological therapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy Posts on Medivizor

Searching for patients with chronic myeloid leukemia to try a new combination of targeted treatments.

Posted by on Jun 29, 2019 in Leukemia | 0 comments

In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...

Read More

Stopping TKI treatment in chronic myeloid leukemia

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study was an update on the guidelines of stopping tyrosine kinase inhibitor (TKI) therapy in the treatment of chronic myeloid leukemia (CML). New guidelines confirm the safety of stopping TKI therapy in patients with CML. Some background Chronic myeloid leukemia is often treated with TKI therapy. These are drugs which...

Read More

Looking for patients with lung cancer to test a new immunotherapy combination

Posted by on Apr 24, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of durvalumab (Imfinzi) and monalizumab to treat patients with solid tumors, including lung cancer. The main outcomes to be measured are tumor response to the treatment and side effects. The details Cancer is one of the leading causes of death worldwide. Chemotherapy is only of limited...

Read More

Rate of deep molecular response in chronic myeloid leukemia treated with nilotinib

Posted by on Apr 15, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the rate of deep molecular response in patients with newly diagnosed chronic myeloid leukemia who were treated with nilotinib. This study concluded that good molecular response rates are seen in these patients. Some background Molecular response (MR) is a measure of the levels of BCR-ABL1 gene in leukemia...

Read More

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...

Read More

Is reducing the dose of imatinib effective in the treatment of chronic myeloid leukemia?

Posted by on Jan 20, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of reducing the dose of imatinib (Gleevec) in the treatment of chronic myeloid leukemia (CML). Researchers found that a lower dose of imatinib can achieve the same result as a high dose in most patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to...

Read More

Can molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?

Posted by on Jan 12, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...

Read More

Evaluating the safety of ibrutinib in leukemia and lymphoma

Posted by on Oct 20, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...

Read More